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Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy Tyrosine kinase inhibitors (TKI) effective for the therapy of chronic myeloid leukaemia are known to be associated with defective platelet function. Dasatinib, a potent inhibitor of BCR-ABL1 and SRC family kinases (SFK) is recognised to cause aberrant platelet function and can induce bleeding, independent of thrombocytopenia.(1) Platelet function abnormalities are described to a lesser extent with imatinib and bosutinib, but appears not to be affected by nilotinib which may be as a result of the different spectrum and intensity of inhibition of off-target signalling pathways by the individual TKIs. Here we describe abnormal platelet function in patients treated with a novel pan BCR-ABL1 inhibitor, ponatinib, effective in the management of CML resistant to multiple TKIs as well as having efficacy against the T315I mutation.(2) Analysis of 5 consecutive patients receiving ponatinib showed that all patients had prolonged closure times with PFA 100, a sensitive measure of primary haemostasis. (3) Patients had received ponatinib for at least 2 weeks without interruption prior to performing a PFA 100 analysis. The dose intensity varied between 15mg to 45mg of ponatinib daily. Only 2 of 5 patients had low platelet counts (64 and 56 x 10 9 /l). None of the patients were on additional anti-platelet therapy or medication implicated in platelet function abnormalities. All 5 patients had prolonged closure times on Collagen/Epinephrine (>300) and 4 patients had prolonged Collagen/ADP closure times (Table 1) . Haematocrit values for the 5 patients were all within normal range (median 0.43%, 0.38-0.46%). Even allowing for the moderate thrombocytopenia in two patients, the marked abnormalities of PFA100 suggest a primary haemostatic defect. No significant bleeding tendencies were observed in any of the patients thus far.
Despite its tolerable side effect profile, ponatinib has associated side effects due to its activity against other kinases, such as SFK, KIT, VEGFR2, PDGFRα and FGFR1 (2). This interesting and clinically important observation on platelet function could be as a result of ponatinib's potent and broad spectrum of multitargeted activity particularly on PDGFR and SFK. Although the actual mechanism is unknown, ponatinib may affect platelet aggregation by inhibiting key kinases. SFK kinases LYN and FYN play critical roles in early platelet activation by glycoprotein VI, upstream of SYK and PLCγ2 (4) (5) . The effect of ponatinib on platelet function (prolonging closure times) appears to be independent of its thrombocytopenic effect and also dose intensity. Not all of the TKIs inhibit platelet function, and these preliminary results advocate the need for vigilance if subjecting patients on ponatinib to any haemostatic challenges. 
